SI2176220T1 - Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev - Google Patents

Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev

Info

Publication number
SI2176220T1
SI2176220T1 SI200830941T SI200830941T SI2176220T1 SI 2176220 T1 SI2176220 T1 SI 2176220T1 SI 200830941 T SI200830941 T SI 200830941T SI 200830941 T SI200830941 T SI 200830941T SI 2176220 T1 SI2176220 T1 SI 2176220T1
Authority
SI
Slovenia
Prior art keywords
pyrrolidin
derivatives
androgen receptor
receptor modulators
modulators
Prior art date
Application number
SI200830941T
Other languages
English (en)
Slovenian (sl)
Inventor
Atsushi Hasuoka
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of SI2176220T1 publication Critical patent/SI2176220T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200830941T 2007-08-07 2008-08-06 Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev SI2176220T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19
EP08792430A EP2176220B1 (en) 2007-08-07 2008-08-06 Pyrrolidin-2-one derivatives as androgen receptor modulators
PCT/JP2008/064500 WO2009020234A2 (en) 2007-08-07 2008-08-06 Pyrrolidin-2 -one derivatives as androgen receptor modulator

Publications (1)

Publication Number Publication Date
SI2176220T1 true SI2176220T1 (sl) 2013-05-31

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830941T SI2176220T1 (sl) 2007-08-07 2008-08-06 Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev

Country Status (34)

Country Link
US (2) US8420694B2 (enExample)
EP (1) EP2176220B1 (enExample)
JP (1) JP5292390B2 (enExample)
KR (1) KR20100049644A (enExample)
CN (1) CN101821235B (enExample)
AR (1) AR067823A1 (enExample)
AU (1) AU2008284662B2 (enExample)
BR (1) BRPI0814957B8 (enExample)
CA (1) CA2695852C (enExample)
CL (1) CL2008002313A1 (enExample)
CO (1) CO6160326A2 (enExample)
CR (1) CR11266A (enExample)
CY (1) CY1114067T1 (enExample)
DK (1) DK2176220T3 (enExample)
DO (1) DOP2010000053A (enExample)
EA (1) EA017429B1 (enExample)
ES (1) ES2406685T3 (enExample)
GE (1) GEP20125571B (enExample)
HR (1) HRP20130374T1 (enExample)
JO (1) JO2864B1 (enExample)
MA (1) MA31639B1 (enExample)
ME (1) ME01579B (enExample)
MX (1) MX2010001484A (enExample)
MY (1) MY159910A (enExample)
NZ (1) NZ583624A (enExample)
PE (1) PE20090899A1 (enExample)
PL (1) PL2176220T3 (enExample)
PT (1) PT2176220E (enExample)
RS (1) RS52812B (enExample)
SI (1) SI2176220T1 (enExample)
TN (1) TN2010000062A1 (enExample)
TW (1) TWI418543B (enExample)
WO (1) WO2009020234A2 (enExample)
ZA (1) ZA201001289B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008284662B2 (en) * 2007-08-07 2013-07-25 Takeda Pharmaceutical Company Limited Pyrrolidin-2 -one derivatives as androgen receptor modulator
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) * 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
PE20091653A1 (es) * 2008-03-26 2009-11-14 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) * 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
US20150057452A1 (en) * 2012-04-04 2015-02-26 Catylix, Inc. Selective androgen receptor modulators
CN104768544B (zh) 2012-08-09 2017-06-16 迪纳米斯治疗公司 包括葡甲胺或其盐的组合物在制备减少或预防甘油三酯水平增加的药物中的应用
EP2898045B1 (de) 2012-09-21 2018-10-24 Merck Patent GmbH Verbindungen mit einer c-c-dreifachbindung und deren verwendung in flüssigkristallmischungen
RS67458B1 (sr) 2014-03-28 2025-12-31 Univ Duke Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
RS63311B1 (sr) 2016-06-22 2022-07-29 Ellipses Pharma Ltd Ar+ metode lečenja raka dojke
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
CN113382990B (zh) 2019-01-11 2024-11-19 格吕伦塔尔有限公司 取代的吡咯烷酰胺iii
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) * 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
PL346795A1 (en) * 1998-09-22 2002-02-25 Yamanouchi Pharma Co Ltd Cyanophenyl derivatives
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
ATE526959T1 (de) 2001-12-06 2011-10-15 Gtx Inc Behandlung von muskelschwund mit selektiven androgenrezeptormodulatoren
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
WO2003057669A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
MXPA04013001A (es) 2002-06-17 2005-09-12 Univ Tennessee Res Foundation Moduladores del receptor de androgneo selectivo en fuente n y metodos de uso de los mismos.
MXPA05001631A (es) * 2002-08-12 2005-08-19 Takeda Pharmaceutical Derivado de benceno fusionado y su uso.
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
MXPA06013115A (es) * 2004-05-11 2007-02-28 Pfizer Prod Inc Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
AU2005247405A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
EP1753417B1 (en) 2004-06-07 2012-04-04 University Of Tennessee Research Foundation A selective androgen receptor modulator and medical uses thereof
RU2007130558A (ru) 2005-01-10 2009-02-20 Акэдиа Фармасьютикалз Инк. (Us) Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
PT1891038E (pt) 2005-05-13 2008-12-02 Lilly Co Eli N-arilpirrolidinas substituídas como moduladores selectivos do receptor de androgénio
CA2617256C (en) 2005-08-01 2014-07-15 Takeda Pharmaceutical Company Limited Cyclic amine compound
EP1987827A1 (en) * 2006-02-20 2008-11-05 Takeda Pharmaceutical Company Limited Novel pharmaceutical
KR20090030345A (ko) * 2006-07-19 2009-03-24 더 오하이오 스테이트 유니버시티 리서치 파운데이션 선택적인 안드로겐 수용체 모듈레이터, 그 유사체와 유도체, 및 그의 용도
EP2049103A2 (en) * 2006-07-26 2009-04-22 Novartis AG Inhibitors of undecaprenyl pyrophosphate synthase
CA2670976C (en) 2006-11-30 2015-01-27 Atsushi Hasuoka Cyclic amine compound
AU2008284662B2 (en) * 2007-08-07 2013-07-25 Takeda Pharmaceutical Company Limited Pyrrolidin-2 -one derivatives as androgen receptor modulator

Also Published As

Publication number Publication date
PL2176220T3 (pl) 2013-08-30
CR11266A (es) 2010-03-22
CO6160326A2 (es) 2010-05-20
HRP20130374T1 (en) 2013-05-31
CN101821235B (zh) 2012-11-14
TW200916439A (en) 2009-04-16
CN101821235A (zh) 2010-09-01
GEP20125571B (en) 2012-07-10
CL2008002313A1 (es) 2009-05-15
EA017429B1 (ru) 2012-12-28
MA31639B1 (fr) 2010-08-02
US7834051B2 (en) 2010-11-16
AU2008284662A1 (en) 2009-02-12
DOP2010000053A (es) 2010-07-15
PE20090899A1 (es) 2009-08-06
KR20100049644A (ko) 2010-05-12
WO2009020234A3 (en) 2009-04-16
WO2009020234A2 (en) 2009-02-12
TN2010000062A1 (en) 2011-09-26
NZ583624A (en) 2012-06-29
CA2695852A1 (en) 2009-02-12
US8420694B2 (en) 2013-04-16
EA201070246A1 (ru) 2010-08-30
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28
RS52812B (sr) 2013-10-31
EP2176220B1 (en) 2013-03-27
BRPI0814957A2 (pt) 2015-02-03
CA2695852C (en) 2017-01-03
JO2864B1 (en) 2015-03-15
TWI418543B (zh) 2013-12-11
HK1143972A1 (en) 2011-01-21
JP5292390B2 (ja) 2013-09-18
PT2176220E (pt) 2013-04-09
US20090042967A1 (en) 2009-02-12
EP2176220A2 (en) 2010-04-21
ES2406685T3 (es) 2013-06-07
BRPI0814957B8 (pt) 2021-05-25
MX2010001484A (es) 2010-03-04
BRPI0814957B1 (pt) 2019-12-03
JP2010535704A (ja) 2010-11-25
ZA201001289B (en) 2011-04-28
MY159910A (en) 2017-02-15
DK2176220T3 (da) 2013-06-10
CY1114067T1 (el) 2016-07-27
AU2008284662B2 (en) 2013-07-25
AR067823A1 (es) 2009-10-21

Similar Documents

Publication Publication Date Title
HRP20130374T1 (en) Pyrrolidin-2-one derivatives as androgen receptor modulators
SI2094658T1 (sl) Spojine tetrahidrociklopenta(b)indola kot modulatorji androgenskega receptorja
IL200922A0 (en) 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators
SI2297100T1 (sl) Tetrahidrociklopenta(b)indoli kot modulatorji androgenskega receptorja
PL2262785T3 (pl) Pochodne benzofuranowe jako modulatory FXR
ZA200807551B (en) Selective androgen receptor modulators
GB0701992D0 (en) Grehlin Receptor Modulators
IL211821A0 (en) The compounds as the estrogen related receptors modulators and the uses thereof
ZA201101707B (en) Novel imidazolidine compounds as androgen receptor modulators
IL196533A0 (en) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
ZA201002268B (en) Benzothiazoles as ghrelin receptor modulators
IL218696A0 (en) 2-oxo-1- pyrrolidinyl imidazothiadiazole derivatives
IL211822A0 (en) The compounds as the estrogen related receptors modulators and the uses thereof
ZA201104069B (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
ZA200806237B (en) Cannibinoid receptor modulators
PL2288612T3 (pl) Modulatory receptora GABAA
GB0811212D0 (en) CB1 Receptor Modulators
ZA200907546B (en) New progesterone receptor modulators
PL1991559T3 (pl) Pochodne oksy-steroidowe jako selektywne modulatory receptora progesteronu
HK1143376A (en) Benzothiazoles as ghrelin receptor modulators
HK1160114A (en) Novel imidazolidine compounds as androgen receptor modulators
GB0813350D0 (en) Cannabinoid receptor modulators
GB0717998D0 (en) Canabinoid receptor modulators
GB0807710D0 (en) Receptor and modulators thereof